Author

Biao Liu

Intellia Therapeutics (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:CRISPR screen· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Aaron ProdeusiD· 1 shared Allie Luther· 1 shared Birgit C. SchultesiD· 1 shared Bo HaniD· 1 shared Boning ZhangiD· 1 shared Dai LiuiD· 1 shared Ian C. Miller· 1 shared Ishina BalwaniiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Aaron ProdeusORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A differentiated and durable allogeneic strategy applicable to cell therapies

Utsav Jetley, Ishina Balwani, Palak Sharma, Ian C. Miller, Allie Luther, Ivy Dutta, Nithila Saravanan, Surbhi Goel, Qingzhan Zhang, Boning Zhang, Ozgun Kilic, Biao Liu, Bo Han, Dai Liu, Birgit C. Schultes, , Yong Zhang

This paper develops an allogeneic T cell therapy strategy using gene editing to reduce immune rejection and enable off-the-shelf use, showing comparable function to autologous cells.

Cytotherapy · Oct 11, 2025Peer-reviewedBioengineering